antibody

Goat anti-NQO1 Antibody

MBS421428

0.1 mg

300 USD

polyclonal

goat

nonconjugated

human, mouse, rat, dog

western blot, enzyme immunoassay

Antibody

Goat anti-NQO1 Antibody

NQO1

Goat Anti-NQO1 (isoform a) Antibody; NQO1; NAD(P)H dehydrogenase, quinone 1; DTD; QR1; DHQU; DIA4; NMOR1; NMORI; diaphorase-4; diaphorase (NADH/NADPH); diaphorase (NADH/NADPH) (cytochrome b-5 reductase); NAD(P)H: menadione oxidoreductase 1, dioxin-inducible 1; DT-diaphorase; NAD(P)H menadione; NQO1 antibody; NAD(P)H dehydrogenase; quinone 1 antibody; DTD antibody; QR1 antibody; DHQU antibody; DIA4 antibody; NMOR1 antibody; NMORI antibody; diaphorase-4 antibody; diaphorase (NADH/NADPH) antibody; diaphorase (NADH/NADPH) (cytochrome b-5 reductase) antibody; NAD(P)H: menadione oxidoreductase 1; dioxin-inducible 1 antibody; DT-diaphorase antibody; NAD(P)H menadione oxidoreductase 1; dioxin-inducible antibody; NAD(P)H: Quinone acceptor oxidoreductase type 1 antibody; NAD(P)H menadione oxidoreductase 1; dioxin-inducible antibody; NAD(P)H: quinone oxireductase antibody; azoreductase antibody; diaphorase (NADH/NADPH) (cytochrome b-5 reductase) antibody; dioxin-inducible 1 antibody; menadione reductase antibody; phylloquinone reductase antibody; quinone reductase 1 antibody

NAD(P)H dehydrogenase; NAD(P)H dehydrogenase [quinone] 1; NAD(P)H dehydrogenase [quinone] 1; NAD(P)H quinone dehydrogenase 1; Azoreductase; DT-diaphorase; DTD; Menadione reductase; NAD(P)H:quinone oxidoreductase 1; Phylloquinone reductase; Quinone reductase 1; QR1

NQO1

NQO1; NQO1; DTD; QR1; DHQU; DIA4; NMOR1; NMORI; DIA4; NMOR1; DTD; QR1

NQO1_HUMAN

Polyclonal

Goat

Tested: Human, Mouse, Rat, Dog, Pig; Expected from sequence similarity: Human, Mouse, Rat, Dog, Pig

274

SIPTDNQIKARK

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Peptide ELISA (EIA), Western Blot (WB)

Peptide ELISA: Antibody detection limit dilution 1: 64000. Western Blot: Approx 30kDa band observed in Human Kidney and Lung lysates and in Rat and Pig Kidney lysates (calculated MW of 30.9kDa according to NP_000894.1). Recommended concentration: 0. 03-0.1ug/ml.

Immunogen: Peptide with sequence C-SIPTDNQIKARK, from the C Terminus of the protein sequence according to NP_000894.1; NP_001020604.1; NP_001020605.1. Epitope: C Terminus

Note: This products is expected to recognize all three reported isoforms (NP_000894.1, NP_001020604.1 and NP_001020605.1).

4505415

NP_000894.1

NM_000903.2

26,365 Da

AhR Pathway (755436); Dopamine Metabolism Pathway (920995); Estrogen Metabolism Pathway (198898); Keap1-Nrf2 Pathway (198777); Metabolism Pathway (1269956); Metabolism Of Amino Acids And Derivatives Pathway (1270158); Metabolism Of Polyamines Pathway (1270170); Oxidative Stress Pathway (198916); Regulation Of Ornithine Decarboxylase (ODC) Pathway (1270174); Ubiquinone And Other Terpenoid-quinone Biosynthesis Pathway (82939)

This gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. This FAD-binding protein forms homodimers and reduces quinones to hydroquinones. This protein's enzymatic activity prevents the one electron reduction of quinones that results in the production of radical species. Mutations in this gene have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of this protein has been seen in many tumors and is also associated with Alzheimer's disease (AD). Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]

NQO1: a FAD-binding flavoprotein enzyme that that prevents the one electron reduction of quinones that results in the production of radical species. Involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis. Mutations have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. The expression of NQO1 is increased in liver, colon and breast tumors and non-small cell lung cancer (NSCLC) compared with the normal tissues. Moreover, expression levels are also elevated in developing tumors, suggesting a role for NQ01 in the prevention of tumor development. A homozygous common missense variant (NQO1(*)2, rs1800566(T)), that disables NQO1 strongly predicts poor survival among two independent series of women with breast cancer. Studies on NQO1 knockout mice suggest that the lack of NQO1 enzymatic activity changes intracellular redox states resulting in a reduction in apoptosis, which in turn leads to myeloid hyperplasia of bone marrow. Altered expression is associated with Alzheimer's disease (AD). Inhibited by dicoumarol. 2 isoforms of the human protein are produced by alternative splicing. Protein type: EC 1.6.5.2; Oxidoreductase. Chromosomal Location of Human Ortholog: 16q22.1. Cellular Component: cell soma; cytoplasm; cytosol. Molecular Function: cytochrome-b5 reductase activity; identical protein binding; NAD(P)H dehydrogenase (quinone) activity; protein binding; superoxide dismutase activity. Biological Process: aging; negative regulation of catalytic activity; nitric oxide biosynthetic process; positive regulation of neuron apoptosis; regulation of amino acid metabolic process; removal of superoxide radicals; response to estradiol stimulus; response to ethanol; response to nutrient; response to toxin; synaptic transmission, cholinergic; xenobiotic metabolic process

0.1 mg

300 USD